Waikato Hospital   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Hamilton New Zealand (1886)

Organization Overview

First Clinical Trial
2003
NCT00856336
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Waikato Hospital | Waikato Hospital, Hamilton, New Zealand | Waikato Hospital Research Fund | Waikato Hospital Research Unit

Active Ingredients

Drugs in Phase 3 Trials (2)

hydroxyethyl starch (voluven) (1 trial)

sodium chloride (2 trials)

Drugs in Phase 2 Trials (2)

pamrevlumab (1 trial)

sodium bicarbonate (1 trial)

Drugs in Phase 1 Trials (3)

selenocysteine (1 trial)

selenomethionine se-75 (1 trial)

vadimezan (1 trial)

Drugs in Other Trials (1)

albuterol (proventil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 2)

Fibrosis (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Pulmonary Fibrosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 8